Research use only.  Educational reference. Not medical advice. Not for human consumption.
📈 GHRH Analog (Short-Acting)

CJC-1295 without DAC Dosage Protocols: All Vial Sizes

CJC-1295 without DAC (also called Modified GRF 1-29) is a 30-amino-acid synthetic GHRH analog with a half-life of ~30 minutes. It produces a discrete GH pulse rather than sustained elevation.

Choose Your Vial Size

VialFinal volumeConcentrationOne U-100 unit
5 mg3 mL1.67 mg/mL16.67 mcg in 0.01 mLOpen protocol →
10 mg3 mL3.33 mg/mL33.33 mcg in 0.01 mLOpen protocol →

Doses are the same research amounts across sizes; the vial size changes the concentration, so syringe units differ. Always use the table for your exact vial.

Storage Instructions

StateTemperatureDuration
Lyophilized−20°C (−4°F)Up to 24 months, dry & dark
Reconstituted2–8°C (35–46°F)Up to 28 days, protect from light

Important Notes

âš  Research Use Only: CJC-1295 without DAC is investigational.

How This Works

CJC-1295 without DAC contains the same four stabilizing amino acid substitutions as the DAC version (D-Ala2, Gln8, Ala15, Leu27) but lacks the albumin-binding linker. The result is a stable, short-acting GHRH analog producing a discrete GH pulse over ~30 minutes.

Common practice combines CJC-1295 with ipamorelin (a GHRP) — the GHRH stimulates GH release while the GHRP synergistically amplifies it, mimicking the body’s natural feedback patterns.

Potential Benefits & Side Effects

Potential Benefits

Side Effect Profile

Lifestyle Factors

Injection Technique

References

1
Sackmann-Sala L et al. 'Short and long-term effects of GHRH agonists' — Endocrinol Metab Clin, 2017